Telmisartan and carotid intima-media thickness regression: A class effect of angiotensin-receptor blockers?

Hypertension Research

Volumn 31, Issue 12, 2008, Pages 2187-2188

  Ntaios, George ^a   Savopoulos, Christos ^a   Hatzitolios, Apostolos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; IRBESARTAN; LOSARTAN; TELMISARTAN; VALSARTAN; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; BIPHENYL DERIVATIVE; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE;

ARTERIAL WALL THICKNESS; CHRONIC KIDNEY DISEASE; DRUG EFFECT; HUMAN; HYPERTENSION; KIDNEY FAILURE; LETTER; CAROTID ARTERY; INTIMA; NOTE; PATHOLOGY; TUNICA MEDIA;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; BIPHENYL COMPOUNDS; CAROTID ARTERIES; HUMANS; LOSARTAN; TETRAZOLES; TUNICA INTIMA; TUNICA MEDIA; VALINE;

EID: 61949191073     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.2187     Document Type: Letter

References (13)

1. Nakamura T, Inoue T, Suzuki T, et al: Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency. Hypertens Res 2008; 31: 841-850.
2. Ludwig M, Stapff M, Ribeiro A, et al: Comparison of the effects of losartan and atenolol on common carotid artery intima-media thickness in patients with hypertension: Results of a 2-year, double-blind, randomized, controlled study. Clin Ther 2002; 24: 1175-1193.
3. Tedesco MA, Natale F, Calabrò R: Effects of monotherapy and combination therapy on blood pressure control and target organ damage: A randomized prospective intervention study in a large population of hypertensive patients. J Clin Hypertens (Greenwich) 2006; 8: 634-641.
4. Olsen MH, Wachtell K, Neland K, et al: Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. Blood Press 2005; 14: 177-183.
5. Sonoda M, Aoyagi T, Takenaka K, Uno K, Nagai R: A one-year study of the antiatherosclerotic effect of the angiotensin-II receptor blocker losartan in hypertensive patients. A comparison with angiotension-converting enzyme inhibitors. Int Heart J 2008; 49 95-103.
6. Uchiyama-Tanaka Y, Mori Y, Kishimoto N, et al: Comparison of the effects of quinapril and losartan on carotid artery intima-media thickness in patients with mild-to-moderate arterial hypertension. Kidney Blood Press Res 2005; 28: 111-116.
7. Ariff B, Zambanini A, Vamadeva S, et al: Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension. Stroke 2006; 37: 2381-2384.
8. Ono H, Minatoguchi S, Watanabe K, et al: Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension. Hypertens Res 2008; 31: 271-279.
9. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Itoh H: Benefits of candesartan on arterial and renal damage of nondiabetic hypertensive patients treated with calcium channel blockers. Am J Nephrol 2006; 26: 462-468.
10. Tomás JP, Moya JL, Barrios V, et al: Effect of candesartan on coronary flow reserve in patients with systemic hypertension. J Hypertens 2006; 24: 2109-2114.
11. Okura T, Watanabe S, Kurata M, et al: Long-term effects of angiotensin II receptor blockade with valsartan on carotid arterial stiffness and hemodynamic alterations in patients with essential hypertension. Clin Exp Hypertens 2008; 30: 415-422.
12. Kosch M, Levers A, Lang D, et al: A randomized, doubleblind study of valsartan versus metoprolol on arterial distensibility and endothelial function in essential hypertension. Nephrol Dial Transplant 2008; 23: 2280-2285.
13. Mörtsell D, Malmqvist K, Held C, Kahan T: Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: The Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study. J Intern Med 2007; 261: 472-479.